錦藝集團控股(00565.HK)中期盈轉虧至2.18億港元
格隆匯 2 月 26日丨錦藝集團控股(00565.HK)公佈,截至2020年12月31日止6個月,公司收益9200萬港元,同比增加3.44%;公司擁有人應占淨虧2.18億港元,去年則溢利935萬港元,盈轉虧;每股淨虧8.1港仙。
期內,由於集團於期內將佳潮購物中心持作投資物業,故集團收益包括已收及應收租户每月租金、管理及營運服務收入。集團收益亦包括向租户招租購物中心C區而賺取的收入。期內收益略微增加乃由於租金、管理及營運服務收入略微增加。
此外,於截至2019年及2020年12月31日止期間,生物科技分類概無錄得收益,原因為於初創階段尚未正式開始生產且生產線處於試行當中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.